Rob Iannone News Today

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,...

As zanidatamab awaits an FDA decision, Jazz is sharing long-term phase 2 data in advanced biliary tract cancer for the HER2-targeted bispecific antibody.

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.

Jazz Pharmaceuticals announced it will present one oral presentation and four poster presentations on narcolepsy and idiopathic hypersomnia.

Study outcomes demonstrated that 80 HER2-postive BTC individuals enrolled in Cohort 1 of the study achieved a confirmed objective response rate of 41.3%

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

Jazz Pharmaceuticals plc misses on earnings expectations. Reported EPS is $5.02 EPS, expectations were $5.26.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript February 28, 2024 Jazz Pharmaceuticals plc misses on earnings expectations. Reported EPS is $5.02 EPS, expectations were $5.26. Jazz Pharmaceuticals plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD).